StockMarketWire.com - Indivior said Monday that its US subsidiary, Indivior, together with Aquestive Therapeutics, had entered into a settlement agreement with Par Pharmaceutical, and IntelGenx Technologies, over a patent dispute related to its drug suboxone.

The settlement would permit Par to begin selling a generic version of suboxone film on January 1, 2023, or earlier under certain circumstances, the firm said.

'We are pleased to have amicably settled another piece of outstanding patent infringement litigation. We continue to seek greater certainty for Indivior, but on terms that adequately reflect the strength of our intellectual property, including the three new Orange Book patents that have been asserted against the remaining ANDA filers,' said Shaun Thaxter, CEO of Indivior.


At 8:10am: [LON:INDV] Indivior Plc share price was -0.5p at 460.6p



Story provided by StockMarketWire.com